Anakinra

14 March, 2024

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

2024-03-14T14:03:07+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, clinical trial, COVID-19, Sepsis|

Evdoxia Kyriazopoulou, Yehudit Hasin‐Brumshtein, Uros Midic, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Myrto Astriti, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vasiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

1 September, 2023

PRECISION

2024-12-11T10:32:19+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

HISS: Facing the LONG-COVID syndrome Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The

27 December, 2022

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

2024-04-03T12:43:50+03:00By hiss|Categories: Publications, Therapeutics|Tags: Anakinra, clinical trial, COVID-19, suPAR|

Karolina Akinosoglou, Antigone Kotsaki, Ioanna-Maria Gounaridi, Eirini Christaki, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Massimo Fantoni, Aggeliki Rapti, Ioannis Kalomenidis, Georgios Chrysos, Gloria Boni, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Asimina Safarika, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

19 December, 2022

Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

2024-04-02T18:36:36+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, clinical trial, COVID-19|

Charilaos Samaras, Evdoxia Kyriazopoulou, Garyfallia Poulakou, Eran Reiner, Maria Kosmidou, Ioanna Karanika, Vasileios Petrakis, George Adamis, Nikolaos K. Gatselis, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, George Chrysos, Giulia Bertoli, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Sofia Koukidou, Glykeria Tzatzagou,

1 November, 2022

Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

2024-04-02T18:31:09+03:00By hiss|Categories: Multicenter studies in Greece, Publications|Tags: Anakinra, clinical trial, Sepsis|

Konstantinos Leventogiannis, Evdoxia Kyriazopoulou, Nikolaos Antonakos, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Inge Grondman, Nikoleta Rovina, Vassiliki Theodorou, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vassileios Koulouras, Apostolos Komnos, Theano Kontopoulou, Athanassios Prekates, Antonia Koutsoukou, Jos WM van der Meer, George Dimopoulos, Miltiades Kyprianou, Mihai G Netea, Evangelos J. Giamarellos-Bourboulis

10 October, 2022

INSPIRE

2024-11-04T11:14:45+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, pneumonia|

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

1 October, 2021

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

2024-04-02T18:13:24+03:00By hiss|Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: Anakinra, clinical trial, COVID-19|

Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, Aggeliki Rapti, Christina Damoulari, Massimo Fantoni, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Maria Tsilika, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Panagiotis Koufargyris, Katerina Dimakou, Spyridon Savvanis, Glykeria

8 March, 2021

An open label trial of anakinra to prevent respiratory failure in COVID-19

2024-03-29T14:13:13+03:00By hiss|Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: Anakinra, COVID-19, suPAR|

Evdoxia Kyriazopoulou, Periklis Panagopoulos, Symeon Metallidis, George N Dalekos, Garyphallia Poulakou, Nikolaos Gatselis, Eleni Karakike, Maria Saridaki, Georgia Loli, Aggelos Stefos, Danai Prasianaki, Sarah Georgiadou, Olga Tsachouridou, Vasileios Petrakis, Konstantinos Tsiakos, Maria Kosmidou, Vassiliki Lygoura, Maria Dareioti, Haralampos Milionis, Ilias C Papanikolaou, Karolina Akinosoglou, Dimitra-Melia Myrodia, Areti Gravvani, Aliki Stamou, Theologia Gkavogianni, Konstantina Katrini,

1 December, 2020

SAVE-MORE

2024-03-14T14:28:56+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by

8 July, 2020

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

2024-03-29T13:31:59+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, COVID-19|

George Dimopoulos, Quirijn de Mast, Nikolaos Markou, Maria Theodorakopoulou, Apostolos Komnos, Maria Mouktaroudi, Mihai G Netea, Themistoklis Spyridopoulos, Rebecca J Verheggen, Jacobien Hoogerwerf, Alexandra Lachana, Frank L van de Veerdonk, Evangelos J. Giamarellos-Bourboulis Cell Host & Microbe 2020 Jul 8;28(1):117-123.e1 DOI 10.1016/j.chom.2020.05.007Download pdf 🡇 Funding The study was funded in part by the